Healthcare Brief Office of National Drug Control Policy Executive Office of the President www.whitehouse.gov/ondcp 1 Medication-Assisted Treatment for Opioid Addiction This document contains a general discussion of medications approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of opioid use disorder. These are extremely complex medical treatments and should be considered only after consultation with a physician who has received training in these therapies for individuals with opioid use disorders. The FDA has approved three medications for use in the treatment of opioid dependence: methadone, naltrexone, and buprenorphine. With an array of medications now available for addressing the emerging prescription painkiller epidemic, it is crucial that providers in both primary and specialty care settings become trained in Medication-Assisted Treatment (MAT), an approach that uses FDA-approved pharmacological treatments, often in combination with psychosocial treatments, for patients with opioid use disorders. Equally important, insurers and policy makers must strive to learn about available medicines and promote policies that ensure that use of these medications is covered as part of a comprehensive approach to treating prescription and illicit drug dependence. Because those who abuse opioids often abuse other substances as well, and because addiction is a chronic relapsing condition, a comprehensive approach to treatment should include assessment, diagnosis, treatment planning, psychosocial treatment, medication monitoring to promote adherence, and a host of social services to support patients as they build new drug-free lives and enter long-term recovery. Services may need to continue indefinitely, as relapse can be a lifelong risk. Medication Options Opioid Addiction Medications for treating opioid addiction including addiction to narcotic prescription painkillers such as oxycodone and hydrocodone as well as illegal opioids like heroin work by interacting with some of the same receptors in the brain that are triggered by the abused drug. Three types of medications currently are used for treating opioid addiction: agonists, partial agonists, and antagonists. As Nora Volkow, M.D., Director of the National Institute on Drug Abuse (NIDA), has explained, the rapid onset and short duration of an abused drug s euphoric effects contribute to compulsive, escalating drug use. 1 Oral agonists, therefore, are useful because their effects are less intense, come on more slowly, and last longer. 2 Even when receptors are turned on by an agonist-type medication, the slower onset and longer duration of action help prevent withdrawal. Partial agonists, as the name implies, produce
2 effects that are similar to but weaker than those of full agonists. Antagonists work by blocking the action of receptors. Should a patient undergoing treatment with an antagonist-type medication relapse and use the formerly abused substance, that drug s power to trigger the receptors is often blocked or greatly diminished. The following medications are approved by the FDA for use in opioid addiction treatment in conjunction with behavioral therapy: Methadone Methadone, a synthetic opioid, is an agonist that mitigates opioid withdrawal symptoms and, at higher doses, blocks the effects of heroin and other drugs containing opiates. 3 Maintenance of opioid addiction treatment with methadone is approved in conjunction with appropriate social and medical services. 4 Used successfully for more than 40 years in the treatment of opioid dependence, methadone at therapeutic doses (generally 80-120 mg) has been shown to eliminate withdrawal symptoms produced by stopping use of heroin and prescription opiate medications 5 because it acts on the same targets in the brain as those drugs. Methadone compliance reduces injection opioid use, thereby helping to close off one route of HIV transmission for patients. 6 Methadone can be dispensed only at an outpatient opioid treatment program (OTP) certified by SAMHSA and registered with the Drug Enforcement Administration (DEA) or to a hospitalized patient in an emergency. 7 SAMHSA-certified OTP facilities provide daily doses until the patient is deemed stable enough to receive take-home doses. 8 Buprenorphine Buprenorphine, approved by the FDA in 2002 to treat opioid dependence, is a partial opioid agonist that, when dosed appropriately, suppresses withdrawal symptoms. 9,10 Although buprenorphine can produce opioid agonist effects and side effects, such as euphoria and respiratory depression, its maximal effects are generally milder than those of full agonists like heroin and methadone. 11 Physicians are permitted to distribute buprenorphine at intensive outpatient treatment programs that are authorized to provide methadone if providers are trained in its use. 12 Additionally, a special program has been set up so that buprenorphine can be prescribed by physicians in office settings and dispensed by pharmacists. 13 In order to prescribe this medication, physicians must complete a training course and receive a waiver granted by the DEA. 14 Buprenorphine was tested in clinical trials for addiction treatment in the United States both by itself and in combination with naloxone, 15 a drug used to counter the effects of an overdose of opiates such as heroin or morphine. The buprenorphine/naloxone combination is sometimes referred to as Bup/Nx (marketed under the brand name Suboxone ). Formulations approved for drug abuse treatment are intended to be taken sublingually (placed under the tongue and allowed to dissolve). 16 When taken this way, the naloxone has little effect. However, if a patient injects Bup/Nx, the naloxone (an antagonist) enters the bloodstream and will block the buprenorphine, causing the patient to enter opioid withdrawal. 17 This combination formulation may deter abuse through injecting because abusers are motivated to avoid unpleasant withdrawal symptoms. 18 Buprenorphine without naloxone sometimes called buprenorphine mono-formulation or simply bup has been used routinely for inducting patients onto buprenorphine. Induction occurs in the provider s presence, where risk of intravenous use is low and injection deterrence is generally unnecessary. Once patients are stabilized on the mono-formulation, those who can tolerate naloxone are switched to the combination product for ongoing maintenance.
3 Naltrexone Naltrexone is a non-addictive antagonist 19 used in the treatment of opioid dependence. The medication blocks opioid receptors so they cannot be activated. 20 This blockade action, combined with naltrexone s ability to bind to opioid receptors even in the presence of other opioids, helps keep abused drugs from exerting their effects when patients have taken or have been administered naltrexone. 21 As an antagonist, naltrexone does not mimic the effects of opioids. Rather, it simply blocks opioid receptor sites so that other substances present in a patient s system cannot bind to them. If a patient who has been administered naltrexone attempts to continue taking opioids, he or she is unable to feel any of the opioid s effects due to naltrexone s blocking action. Theoretically, it is possible to override the blockade by taking very large doses of opioid, but this is rarely reported because the quantities required are so large. Naltrexone is administered in an injectable long-acting formulation (marketed under the brand name Vivitrol ), sometimes called depot naltrexone, which is designed for once-monthly dosing. 22 The FDA approved this medication for use in people with opioid use disorders to prevent relapse. 23 FDA recommends that Naltrexone should be used only in patients who have been detoxified from opioids and have been opioid free for 7 10 days. 24 Although naltrexone is non-narcotic and non-addictive, as with other medications that interact with the opioid receptors, there is a risk of narcotic overdose if a patient who is being treated with naltrexone misses a dose and takes an opioid, or if the patient takes large quantities of opioids in an attempt to break the blockade. 25,26 Compliance measures that closely monitor patients during the treatment period may be beneficial. Detoxification vs. Stabilization and Maintenance For opioid abusers who do not wish to enter treatment or do not qualify for ongoing maintenance therapy, some treatment programs provide medically assisted detoxification services, which involve weaning patients off addictive substances and managing withdrawal. However, research shows such programs are closely associated with relapse. 27 And because tolerance to opioids fades rapidly even during a short period of abstinence, one episode of opioid misuse following detoxification can result in a life-threatening or deadly overdose. Before medications became available for addiction treatment, detoxification routinely took place at the beginning of treatment. This is still the case in programs that set complete drug abstinence as a goal and in the treatment of addictions for which medications are not yet approved. However, in the case of methadone, researchers supported by the National Institute on Drug Abuse (NIDA) formulated a phased approach that does not necessarily emphasize complete detoxification. 28,29 This approach, recently expanded, has been recommended by a consensus panel from the Substance Abuse and Mental Health Services Administration (SAMHSA). According to the phased approach, the first step in treatment is not detoxification. Rather, it involves intensive stabilization, including withdrawal management, assessment, medication induction, and involvement in psychosocial counseling. The middle phase of care emphasizes medication maintenance and deeper work in and out of counseling on patient goals. In the third phase, ongoing rehabilitation, the patient and provider might choose to detoxify from all medication or pursue indefinite maintenance, depending on the patient s needs. 30,31 Treatment in a phased model, regardless of how long medication is used, involves participation in psychosocial treatment, and engagement with the self-help community is recommended. As such, participants in MAT can transition to a lifestyle consistent with being in recovery while using FDA-approved medication to treat their substance use disorder.
4 One study found it was common for patients in long-term methadone maintenance who taper off their medicine (gradually reduce their doses) to fail during the process or relapse within 6 months of becoming abstinent. 32 The SAMHSA consensus group recommended that detoxification be optional and that patients never be coerced into tapering. 33 Research in which patients have been discontinued from buprenorphine also shows high rates of relapse. 34 For this reason, ongoing MAT may be the safest and best approach for opioid rehabilitation. Resources These free resources provide more information about Medication-Assisted Treatment: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction http://buprenorphine.samhsa.gov/bup_guidelines.pdf Medication-Assisted Treatment for Opioid Addiction: Facts for Family & Friends http://store.samhsa.gov/shin/content/sma09-4443/sma09-4443.pdf NIDA Info Facts: Treatment Approaches to Drug Addiction http://www.drugabuse.gov/publications/infofacts/treatment-approaches-drug-addiction Medication Assisted Therapy Toolkit http://www.niatx.net/pdf/niatx-mat-toolkit.pdf SAMHSA Treatment Locator 1-800-662-HELP http://www.findtreatment.samhsa.gov/
FDA-Approved Medications for Substance Use Disorders Name Molecular Structure Naltrexone (Vivitrol ) Buprenorphine Methadone Antagonist Agonist Agonist Treatment Use Opioid dependence Opioid dependence Opioid dependence Controlled Substance? Schedule 0 Schedule III Schedule II 5 Abuse Potential No Yes Yes Trade Name Vivitrol Suboxone * *includes naloxone Methadone How administered Intramuscular injection Oral tablet or sublingual film taken once daily Oral Solution How the medication works By blocking opioid receptors, it blocks cuetriggered craving A long-acting partial opioid, it relieves withdrawal, decreases craving, and prevents euphoria if other opioids are used A long-acting full opioid that relieves withdrawal, blocks craving, and prevents euphoria if other opioids are used Special licensing or credential required? No Varies by state Yes Year approved by FDA for Addiction Treatment Physician training required? 2006 2002 No Yes 8 hours of training required 1947 - Approved dispersible tablet for treatment of addiction Typical Duration Up to 30 days 1 day 1 day No Detoxification or Stabilization Detoxification & 7 10 days of complete abstinence from opioids Detoxification Can be used for detoxification and/or stabilization Adapted from Getting Started with Medication-assisted Treatment, NIATx (2010). Notes 1 Nora Volkow, M.D., Director, National Institute on Drug Abuse (NIDA). 2 Gerra G., Maremmani I., Capovani B., Somaini L., Berterae S., Tomas-Rossello J., Saenz E., Busse A., & Kleber H. (2009). Long-Acting Opioid-Agonists in the Treatment of Heroin Addiction: Why Should We Call Them Substitution? Substance Use Misuse. 44(5), 663-671. 3 U.S. Food and Drug Administration. Methadone Oral Concentrate (methadone hydrochloride oral concentrate USP) and Methados Sugar-Free Oral Concentrate (methadone hydrochloride oral concentrate USP) dye-free, sugar-free, unflavored. Retrieved 02/28/2012 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017116s021lbl.pdf 4 Ibid.
6 5 U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Division of Pharmacologic Therapies. Methadone. Retrieved 02/28/2012 from http://dpt.samhsa.gov/medications/methadone.aspx. 6 Ball, J.C, Lange, R.W., Myers, P. & Friedman, S. R. Reducing the Risk of AIDS Through Methadone Maintenance Treatment. Journal of Health and Social Behavior, Vol. 29, No. 3 (Sep., 1988), pp. 214-226 7 U.S. Food and Drug Administration. Methadone Oral Concentrate (methadone hydrochloride oral concentrate USP) and Methadone Sugar- Free Oral Concentrate (methadone hydrochloride oral concentrate USP) dye-free, sugar-free, unflavored. Retrieved 02/28/2012 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017116s021lbl.pdf 8 U.S. Food and Drug Administration. (2002). Subutex and Suboxone approved to treat opiate dependence: Postmarket Drug Safety Information for Patients and Providers. Retrieved 2/28/2012 from http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm191521.htm 9 U.S. Food and Drug Administration. (2002). Subutex and Suboxone approved to treat opiate dependence: Postmarket Drug Safety Information for Patients and Providers. Retrieved 2/28/2012 from http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm191521.htm 10 U.S. Food and Drug Administration. Suboxone Tablet (Reckitt) label. See Section 12.1 and 12.2 for discussion of partial agonist effects and withdrawal section 2.1 of full prescribing information for information on suppressing withdrawal. Retrieved 07/05/2012 from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b9b43c4-293e-4323-a1a1-9a2f6a16ac39 11 Ibid. 12 The SAMHSA Evaluation of the Impact of the DATA Waiver Program Summary Report FINAL. Task Order 277-00-6111. March 30, 2006, linked to on July 5, 2012. Available at http://buprenorphine.samhsa.gov/for_final_summaryreport_colorized.pdf 13 U.S. Food and Drug Administration. (2002). Subutex and Suboxone approved to treat opiate dependence: Postmarket Drug Safety Information for Patients and Providers. Retrieved 2/28/2012 from http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm191521.htm 14 The SAMHSA Evaluation of the Impact of the DATA Waiver Program Summary Report FINAL. Task Order 277-00-6111. March 30, 2006, linked to on July 5, 2012. Available at http://buprenorphine.samhsa.gov/for_final_summaryreport_colorized.pdf 15 U.S. Food and Drug Administration. Suboxone Tablet (Reckitt) label. Retrieved 07/05/2012 from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b9b43c4-293e-4323-a1a1-9a2f6a16ac39 16 U.S. Food and Drug Administration. Suboxone Tablet (Reckitt) label. Retrieved 07/05/2012 from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b9b43c4-293e-4323-a1a1-9a2f6a16ac39 17 Ibid. 18 Comer, S., Sullivan, M., Vosburg, S., Manubay, J., Amass, A., Cooper, Z., Saccone, P. & Kleber, H. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction, 105, 709 718. 19 U.S. Food and Drug Administration. (2002). Subutex and Suboxone approved to treat opiate dependence: Postmarket Drug Safety Information for Patients and Providers. Retrieved 2/28/2012 from http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm191521.htm 20 U.S. Food and Drug Administration. Vivitrol label. Retrieved 02/28/2012 from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703f 21 Ibid. 22 Ibid. 23 Ibid. 24 U.S. Food and Drug Administration. Vivitrol label. Retrieved 02/28/2012 from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703f 25 Ibid. 26 Benyamina A., Reynaud M., Blecha L., Karila L. (2011). Pharmacological treatments of opiate dependence. Current Pharmaceutical Design, 17(14): 1384-8. 27 Day, E., & Strang, J. (2010). Outpatient versus inpatient opioid detoxification: a randomized controlled trial [Electronic Version]. Journal of Substance Abuse Treatment. 40 (1), 56-66. 28 Moolchan, E.T., & Hoffman, J.A. (1994). Phases of treatment: a practical approach to methadone maintenance treatment [electronic version]. International Journal of the Addictions. 29 (2), 135-160. 29 Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2005. (Treatment Improvement Protocol (TIP) Series, No. 43.) Available at http://www.ncbi.nlm.nih.gov/books/nbk64164 30 Ibid. 31 Moolchan, E.T., & Hoffman, J.A. (1994). Phases of treatment: a practical approach to methadone maintenance treatment [Electronic Version]. International Journal of the Addictions. 29 (2), 135-160. 32 Calsyn, D.A., Malcy, J.A., & Saxon, A.J. (2006). Slow tapering from methadone maintenance in a program encouraging indefinite maintenance [Electronic Version]. Journal of Substance Abuse Treatment. 30 (2), 159-163. 33 Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2005. (Treatment Improvement Protocol (TIP) Series, No. 43.) Available at http://www.ncbi.nlm.nih.gov/books/nbk64164 34 Weiss, R.D., Potter, J.S., Fiellin, D.A., Byrne, M., Connery, H.S., Dickinson, W., Gardin, J., Griffin, M.L., Gourevitch, M.N., Haller, D.L., Hasson, A.L., Huang, Z., Jacobs, P., Kosinski, A.S., Lindblad, R., McCance-Katz, E.F., Provost, S.E., Selzer,.J, Somoza, E.C., Sonne, S.C., Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry, Dec;68(12):1238-46.
From NIATx Medication Assisted Treatment (MAT) Toolkit (2010). Access the complete toolkit here: http://www.niatx.net/pdf/niatx-mat-toolkit.pdf
Are Drinking or Drugging Becoming a Problem for You or a Loved One? You re not alone, and we d like to make you aware of mutual-help support groups offering a variety of free services for you to consider. The organizations provide face-to-face meetings and online activities. For those of you who may be isolated geographically or have limited time for face-to-face meetings, online meetings and activities are proving very useful in supporting efforts at recovery. While 12-step programs remain a solid option, you may not be familiar with some of these alternative programs that can help you to regain a rewarding and fulfilling life. A brief overview of each program is provided in this publication, and do feel free to visit the organizations websites for more complete information about each of the programs. www.lifering.org www.sossobriety.org www.womenforsobriety.org www.moderation.org www.smartrecovery.org www.facesandvoicesofrecovery.org
LifeRing LifeRing offers sober, secular self-help to abstain from alcohol and non-medically-indicated drugs by relying on our own power and the support of others. We welcome people from all faiths, or none, but our spiritual beliefs if any, are personal. LifeRing brings people together via face-to-face and online support groups and provides sobriety tools through original books, publications and interactive online resources. LifeRing meetings are friendly, confidential, nonjudgmental gatherings of peers. The atmosphere is relaxed, practical and positive. Members of other recovery programs are welcome in LifeRing meetings. For additional information, visit www.lifering.org SMART Recovery SMART Recovery participants learn tools for recovery based on the latest scientific research and participate in a world-wide community which includes free selfempowering, science-based mutual help groups. The SMART Recovery 4-Point Program helps people recover from all types of addiction and addictive behaviors, including substances and activities. Points: 1) Enhancing/ maintaining motivation to abstain; 2) Coping with urges; 3) Managing thoughts, feelings and behavior (problem-solving); and 4) Balancing momentary and enduring satisfactions (lifestyle balance). SMART Recovery sponsors face to face meetings worldwide and has daily online meetings. Our online message board and 24/7 chat room provide excellent forums to learn about SMART Recovery and obtain addiction recovery support. For additional information, visit www.smartrecovery.org Women for Sobriety WFS is a self-help program for women with problems of addiction. It is the first and only self-help program for women only and its precepts take into account the very special problems women have in recovery the need for feelings of self-value and self-worth, and the need to expatiate feelings of guilt and humiliation. Women for Sobriety is an organization whose purpose is to help all women recover from problem drinking through the discovery of self, gained by sharing experiences, hope and encouragement with other women in similar circumstances. Women for Sobriety is unique as an organization of women for women. It recognizes woman s emerging role and her necessity for self-esteem and self-discovery to meet today s conflicts. For additional information, visit www.womenforsobriety.org. SOS International SOS/Secular Organizations for Sobriety/Save Our Selves takes a selfempowerment approach to recovery and maintains that sobriety is a separate issue from all else. SOS addresses sobriety (abstinence) as Priority One, no matter what! SOS credits the individual for achieving and maintaining his or her own sobriety. SOS respects recovery in any form, regardless of the path by which it is achieved. It is not opposed to or in competition with any other recovery program. SOS supports healthy skepticism and encourages the use of the scientific method to understand alcoholism. Suggested guidelines for sobriety: To break the cycle of denial and achieve sobriety, we first acknowledge that we are alcoholics or addicts; We reaffirm this truth daily and acknowledge without reservation that, as clean and sober individuals, we cannot and do not drink or use no matter what; Since drinking or using is not an option for us, we take whatever steps are necessary to continue our Sobriety Priority lifelong; A quality of life the good life can be achieved. However, life is also filled with uncertainties. Therefore, we do not drink or use regardless of feelings, circumstances, or conflicts. We share in confidence with each other our thoughts and feelings as sober, clean individuals. Sobriety is our Priority, and we are each responsible for our lives and our sobriety. For additional information visit www.sossobriety.org. WWW.FACESANDVOICESOFRECOVERY.ORG HAS AN EXTENSIVE RESOURCE SECTION THAT INCLUDES A MORE EXHAUSTIVE LISTING OF MUTUAL HELP GROUPS WITH INFORMATIVE DESCRIPTIONS THAT MAY BE HELPFUL TO YOU. While the previously-noted organizations are abstinence based, if you are just beginning to believe you may need to reduce and moderate your alcohol intake, please consider Moderation Management. Moderation Management MM is an international mutual aid support group which offers education, behavioral change techniques and peer support for problem drinkers seeking to decrease their drinking, whether to moderate levels or to total abstinence. MM is particularly appropriate for problem drinkers whose drinking would not be categorized as dependent. It is a good first step for those unwilling or unable to just say no or to join an abstinence program. Its concrete guidelines, limits and techniques give experiential information for each participant to discover whether moderate drinking can be a viable solution. MM offers a variety of behavioral methods for change, guidelines for responsible drinking, and tools to measure progress. The MM approach encourages reading and discussion and assumes personal responsibility. Group support and shared experiences enhance the belief that moderate drinking is within personal control. MM is available in face-to-face meetings in the US and other countries and in an online program. The online program features a member listserv, forum, chatrooms, online meetings, an abstinence group, listings of moderation-friendly therapists, and Abstar, the online drink counter. See also: Responsible Drinking: A Moderation Management Approach for Problem Drinkers (Rotgers, et al., 2002); Interactive web application, Moderate Drinking, moderateddrinking.com (Reid Hester, Behavior Therapy Associates, LLP). For additional information, visit: www.moderation.org.
Mutual Support Groups Alcoholics Anonymous (AA) World Services P.O. Box 459 New York, NY 10163 Phone: 212.870.3400 Web: www.aa.org LifeRing 1440 Broadway Suite 312 Oakland, CA 94612-2023 Phone: 510.763.0779 Toll-Free: 800.811.4142 Email: service@lifering.org Web: www.lifering.org Moderation Management (MM) 2795 East Bidwell Street Suite 100-244 Folsom, CA 95630-6480 Phone: 212.871.0974 Email: mm@moderation.org Web: www.moderation.org Secular Organizations for Sobriety/Save Our Selves (SOS) 4773 Hollywood Blvd. Hollywood, CA 90027 Phone: 323.666.4295 Email: sos@cfiwest.org Web: www.sossobriety.org SMART Recovery 7304 Mentor Avenue, Suite F Mentor, OH 44060 Phone: 440.951.5357 Fax: 866.951.5357 Email: information@smartrecovery.org Web: www.smartrecovery.org Women for Sobriety (WFS) P.O. Box 618 Quakertown, PA 18951-0618 Phone: 215.536.8026 Email: newlife@nni.com Web: www.womenforsobriety.org Narcotics Anonymous (NA) P.O. Box 9999 Van Nuys, CA 91409 Phone: 818.773.9999 Email: fsmail@na.org Web: www.na.org